Literature DB >> 17547850

The spectrum of multiple sclerosis.

Robert N S Heard1.   

Abstract

Multiple sclerosis (MS) is the most common cause of chronic neurologic disability in young people. Genetic susceptibility and unidentified environmental triggers appear to be necessary in order to result in disease. MS is an extraordinarily complex trait with evidence of heterogeneity at clinical, pathologic, and therapeutic levels. Recent studies have not resolved the important question whether at a mechanistic level MS is a single disease with a wide spectrum of clinical expression, or whether it encompasses a group of separate diseases that share certain pathologic final common pathways. This question is important not only for helping to understand the causes of MS but also for designing and applying better treatments.

Entities:  

Mesh:

Year:  2007        PMID: 17547850     DOI: 10.1007/s11882-007-0042-y

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  24 in total

1.  Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion.

Authors:  Michael H Barnett; John W Prineas
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

Review 2.  Infectious causes of multiple sclerosis.

Authors:  Gavin Giovannoni; Gary R Cutter; Jan Lunemann; Roland Martin; Christian Münz; Subramaniam Sriram; Israel Steiner; Margaret R Hammerschlag; Charlotte A Gaydos
Journal:  Lancet Neurol       Date:  2006-10       Impact factor: 44.182

3.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

4.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

5.  Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis.

Authors:  Anna Jurewicz; Mariola Matysiak; Cedric S Raine; Krzysztof Selmaj
Journal:  Neurology       Date:  2007-01-23       Impact factor: 9.910

6.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

7.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

8.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

Review 9.  Remyelination in multiple sclerosis.

Authors:  Wolfgang Brück; Tanja Kuhlmann; Christine Stadelmann
Journal:  J Neurol Sci       Date:  2003-02-15       Impact factor: 3.181

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  4 in total

1.  Meeting the needs of people with primary progressive multiple sclerosis, their families, and the health-care community.

Authors:  Nancy J Holland; Diana M Schneider; Robert Rapp; Rosalind C Kalb
Journal:  Int J MS Care       Date:  2011

Review 2.  Autophagy, inflammation and neurodegenerative disease.

Authors:  Mehrdad Alirezaei; Christopher C Kemball; J Lindsay Whitton
Journal:  Eur J Neurosci       Date:  2010-12-07       Impact factor: 3.386

Review 3.  Pharmacometrics: The Already-Present Future of Precision Pharmacology.

Authors:  Lorena Cera Bandeira; Leonardo Pinto; Cláudia Martins Carneiro
Journal:  Ther Innov Regul Sci       Date:  2022-08-18       Impact factor: 1.337

4.  Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.

Authors:  Jeri Burtchell; Kristen Fetty; Katelyn Miller; Kit Minden; Daniel Kantor
Journal:  Neurol Ther       Date:  2019-07-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.